ANDA 218850, held by Specgx LLC. Lisdexamfetamine Dimesylate.
As of Nov 16, 2026, ANDA 218850 (Lisdexamfetamine Dimesylate), held by Specgx LLC, was first approved by FDA on Dec 17, 2024, with 0 approved supplements and 0 published complete response letters.
Lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Moderate to severe binge eating disorder (BED) in adults. Limitations of Use: The use of lisdexamfetamine dimesylate chewable tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. Lisdexamfetamine dimesylate chewable tablets are not indicated or recommended for weight loss.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 17, 2024 | Original application | Approved | None posted |
| Lisdexamfetamine Dimesylate10MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate20MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters